VENTURE CAPITAL POST

Aiming to continue the expansion of the biotech sphere and looks to boost its food-allergy programs, Nestlé Health Science has financed $145 million into Aimmune ($AIMT).

Shares of the German pharmaceutical and chemical giant increased by 5% in Monday trading. Monsanto's interest to acquire its crop science business triggered the surge.

South Korean venture capital firms are eyeing overseas biotech industry to accelerate investment goals. At the sametime, tech startups in Korea also began to flourish.

San Fransisco-based biotech accelerator IndieBio is determined to help biotech startups the way other accelerators have done for IT startups. The firm believes that biotech is a highly important sector to boost the quality of humanity and economy, and is convincing other investors to have the same vision.

China's government has kicked off a media campaign in support of genetically modified crops, as it battles a wave of negative publicity over a technology it hopes will play a major role in boosting its food security.

Hundreds of companies around the world are chasing an emerging market for cheaper copies of costly biotech drugs, with more than 700 so-called biosimilars now in development or already approved, according to a major study of the sector.

Benchling, a startup backed by YCombinator, SV Angel, Founders Fund, Draper Associates and other angels, bridges biotechnology and computer science with their DNA editing software.

Biotech companies are in a rush to go public partly due to the sky-high valuations now experienced by many biotech firms that have gone public in the past few years, the Venture Capital Dispatch reported.

The personal genomic and biotechnology corporation in the US would target people's DNA by selling their genetic information for US$99.

Biotech Corp said that it has already passed its investment target for this year.

Conactus Pharmaceutical raised US $66 million after the company offered 6,000,000 shares at US $11 each during the initial public offering.

Cleveland BioLabs and other biotech firms have stated their desire to move their development operations to Russia.

Heliae raise US$28.4 million from current and new investors to promote algae-based specialty merchandises.

Edward (Ted) Marple takes the lead of the research organization as its founder Paul Wengender focus on the business aspect.

Temasek Holdings from Singapore pledged to invest into Celltrion.